Study guide
11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices
AACN Cardiac Medicine Certification CMC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview and the CMC Test Plan
1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them
2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease
2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease
3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup
4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions
4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation
5 Chapter 5: Vascular Conditions and Vascular Interventions
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications
6 Chapter 6: Shock States and Mechanical Circulatory Support
6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD
7 Chapter 7: Cardiac Procedures and Structural Heart Interventions
7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications
8 Chapter 8: Cardiovascular Pharmacology
8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure
9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary
9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients
10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral
10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients
11 Chapter 11: Monitoring and Diagnostics
11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography
12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions
12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease
11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices
Key Takeaways Explain This Topic AI
Match the monitor to symptom frequency: daily symptoms get a 24-48 hour Holter, several-times-weekly symptoms get a 7-14 day patch, weekly-to-monthly symptoms get a 30-day event or loop recorder or mobile cardiac telemetry, and symptoms less often than monthly get an implantable loop recorder, which records for about 3 years.
Remote monitoring with at least annual in-person evaluation is a Class I recommendation for all eligible patients with a cardiac implantable electronic device, and it transmits battery and elective replacement indicator status, lead impedance and thresholds, arrhythmia episodes with electrograms, delivered therapies, and heart-failure diagnostics such as thoracic impedance.
The CardioMEMS pulmonary artery sensor is read by the patient at home each morning; pulmonary artery diastolic pressure approximates left ventricular filling pressure, and a rising trend precedes weight gain and symptoms by one to three weeks, which is the entire clinical value of the device.
CHAMPION showed a 37% reduction in heart-failure hospitalisation with pulmonary artery pressure-guided management, and the 2022 AHA/ACC/HFSA heart failure guideline gives the strategy a Class 2b recommendation in selected NYHA class III patients with a prior hospitalisation.
Lead II is the best lead for atrial activity, but V1 or MCL1 is the lead that distinguishes ventricular tachycardia from supraventricular tachycardia with aberrancy, and more than 85% of inpatient telemetry alarms are false or non-actionable, which is why daily electrode change, skin prep and patient-specific alarm limits are an evidence-based safety intervention.
Last updated: August 2026
Why This Is a Nursing Competency, Not an Electrophysiology Topic
Test-plan item IV.A.6 covers remote monitoring . Almost none of the examinable content is about how the devices work internally. It is about choosing the right monitor for a given symptom pattern, coaching adherence, triaging an alert, and knowing when a transmission or an alarm requires action tonight versus at the next clinic visit. A monitoring programme without a defined ownership and escalation pathway is a patient-safety liability, and CMC scenarios frequently turn on who acts and when.
Ambulatory Rhythm Monitoring
Device Duration Recording behaviour Best suited to
Holter monitor (continuous 3- to 12-channel) 24-48 hours, occasionally up to 7 days Continuous, retrospective review of everything Daily symptoms; quantifying premature ventricular contraction burden, atrial fibrillation burden, QT and heart-rate variability
Adhesive patch monitor 7-14 days, some up to 30 Continuous single-lead, retrospective, patient-triggered marks Symptoms occurring at least weekly ; consistently higher diagnostic yield than a Holter because of the longer wear time
Patient-activated event recorder Up to 30 days Records only when the patient presses the button Infrequent but sustained symptomatic episodes the patient has time to capture
External loop recorder Up to 30 days Continuous loop memory that saves the seconds before and after a trigger Brief symptoms and near-syncope, where the event ends before the patient can activate the device
Mobile cardiac outpatient telemetry (MCOT) Up to 30 days Continuous with automatic arrhythmia detection and real-time cellular transmission to a monitoring centre Infrequent but potentially dangerous arrhythmia where near-real-time notification changes management
Implantable loop recorder / insertable cardiac monitor About 3 years (newer generations longer) Continuous auto-detection plus patient activation, interrogated remotely Syncope occurring less often than monthly , cryptogenic stroke atrial fibrillation surveillance, palpitations after non-diagnostic external monitoring
Consumer wearable (single-lead ECG smartwatch, photoplethysmography) Indefinite Opportunistic or user-initiated Patient-initiated documentation and selected screening; never a diagnostic endpoint on its own
The Decision Rule
Match the length of the monitoring window to the frequency of the symptom. This is the single highest-yield concept in this section.
- Symptoms daily to several times daily → 24-48 hour Holter
- Symptoms several times per week → 7-14 day patch
Symptoms roughly weekly to monthly → 30-day event or loop recorder; use MCOT instead when a dangerous rhythm is suspected and real-time notification matters
Symptoms less often than monthly , or unexplained syncope with structural heart disease or injury → implantable loop recorder
Cryptogenic stroke needing atrial fibrillation surveillance → implantable loop recorder, because paroxysmal atrial fibrillation is frequently missed by 30 days of external monitoring
Only a minority of Holter studies capture a symptomatic event, and a normal Holter in a patient with monthly symptoms proves nothing at all . The endpoint of ambulatory monitoring is symptom-rhythm correlation , not simply rhythm detection, which is why the symptom diary is not optional paperwork. Teach the patient to log the time, activity, duration and symptom for every event, and to press the trigger even if the episode has already ended on a loop-recording device.
Consumer Wearables
Single-lead smartwatch ECGs and photoplethysmography-based irregular-rhythm notifications generate a large volume of nurse phone calls. Their positive predictive value is modest — only about a third of irregular-rhythm notifications in the largest screening study were confirmed as atrial fibrillation on subsequent patch monitoring — and motion, poor contact and premature beats all trigger false alerts. The nursing answer to a patient reporting a watch alert is confirm, do not dismiss and do not act : arrange a medical-grade recording or a 12-lead ECG. Anticoagulation is never started on a consumer wearable tracing alone.
- Remote Monitoring of Cardiac Implantable Electronic Devices
- What Is Transmitted
Category Data elements Why the nurse cares
Battery and hardware Battery voltage and longevity, elective replacement indicator (ERI) and end of service, lead impedance, pacing thresholds and sensing amplitudes A sudden impedance rise suggests lead fracture; a sudden fall suggests insulation breach. Either can cause failure to pace or inappropriate shocks from noise
Pacing performance Percentage of atrial and ventricular pacing; for cardiac resynchronisation therapy, biventricular pacing percentage (target 98-99% or higher) A CRT patient with falling biventricular pacing from atrial fibrillation with rapid conduction or frequent PVCs loses the entire benefit of the device
Arrhythmia Atrial high-rate episodes with duration and burden, mode switches, non-sustained and sustained ventricular tachycardia, stored electrograms Newly detected atrial high-rate episodes drive stroke-risk discussion; episode electrograms distinguish real ventricular tachycardia from oversensing
Therapy Anti-tachycardia pacing attempts, number and timing of shocks, success or failure Multiple shocks means electrical storm until proven otherwise; a single appropriate shock in an asymptomatic patient is triaged differently
Heart-failure diagnostics Intrathoracic or thoracic impedance fluid index, night heart rate, heart-rate variability, activity level, and composite risk scores A falling thoracic impedance with a rising night heart rate and reduced activity is an early congestion signature
Scheduled transmissions occur at defined intervals, commonly every 91 days, and simply replace a routine clinic interrogation. Alert-driven transmissions fire immediately for pre-set conditions: out-of-range lead impedance, ERI or end of service, sustained ventricular tachycardia or fibrillation, delivered shocks, and new atrial fibrillation with rapid rates.
Remote interrogation combined with at least an annual in-person evaluation is a Class I recommendation for all eligible device patients, and registry data have linked it to earlier detection of actionable events and better survival. Practical nursing points: verify the transmitter is powered, paired and within range; confirm the patient understands that remote monitoring is not an emergency system — a patient who is shocked and symptomatic calls 911, not the device clinic; and remember the magnet rule, because a magnet over an implantable cardioverter-defibrillator suspends tachytherapy without changing the pacing mode , whereas a magnet over a pacemaker produces asynchronous pacing.
Implantable Hemodynamic Monitoring: The Pulmonary Artery Pressure Sensor
The CardioMEMS system is a batteryless, leadless microelectromechanical sensor implanted by right heart catheterisation into a distal branch of the left pulmonary artery. It is powered by radiofrequency energy from an external electronics unit built into a pillow.
How it is used. The patient lies on the pillow at the same time each day, usually in the morning before the diuretic dose, and the reading uploads automatically to a secure clinician portal. The team sees pulmonary artery systolic, diastolic and mean pressures.
Why the pulmonary artery diastolic pressure is the number that matters. In the absence of significant pulmonary vascular disease, pulmonary artery diastolic pressure approximates pulmonary capillary wedge pressure and therefore left ventricular filling pressure. Hemodynamic congestion precedes weight gain and symptoms by one to three weeks. A rising trend allows the diuretic to be titrated, a thiazide added, or vasodilator and guideline-directed medical therapy adjusted before the patient becomes symptomatic. This lead time is the entire clinical rationale for the device.
Evidence and guideline position. CHAMPION demonstrated a 37% reduction in heart-failure hospitalisation at 6 months with pressure-guided management. GUIDE-HF missed its overall primary endpoint in a trial heavily disrupted by the COVID-19 pandemic, though the pre-pandemic analysis favoured monitoring, and MONITOR-HF showed improved quality of life. The 2022 AHA/ACC/HFSA heart failure guideline gives pulmonary artery pressure-guided management a Class 2b recommendation in selected NYHA class III patients with a prior heart-failure hospitalisation or persistently elevated natriuretic peptides.
Nursing role. Coach daily adherence, because a single reading is meaningless and only a trend guides therapy. Teach that the sensor supplements rather than replaces symptom and weight reporting. Use teach-back on every diuretic change. Arrange electrolyte and renal function follow-up after each titration. Escalate a sustained upward trend rather than waiting for weight gain or orthopnea. Confirm the antiplatelet or anticoagulant course prescribed after implantation, and note that the sensor is MRI-conditional.
Other Remote Programmes
Blood pressure telemonitoring using a validated upper-arm cuff, with attention to cuff size and technique, transmitting averaged readings rather than single values. Self-measured blood pressure monitoring with clinician support is supported by AHA/ACC guidance for confirming hypertension and guiding titration.
Structured telephone support and telehealth heart-failure programmes reduce readmission when — and only when — a clinician is accountable for acting on the data.
Remote left ventricular assist device follow-up using downloaded log files to review flow, power, pulsatility index and alarm history between visits.
- Inpatient Telemetry: Indication Discipline and Alarm Management
- Indications, and the Duty to De-escalate
The AHA practice standards for electrocardiographic monitoring in hospital settings grade indications as Class I (indicated in most or all patients), Class II (may be of benefit), and Class III (not indicated).
Class I examples Class III examples
Early period after resuscitated cardiac arrest Stable patients with chronic rate-controlled atrial fibrillation and no other indication
- Acute coronary syndrome, or chest pain under active evaluation Uncomplicated maintenance hemodialysis
- Newly diagnosed arrhythmia requiring therapy Low-risk chest pain already ruled out by serial troponin and ECG
Post cardiac surgery and complicated post-PCI patients Stable patients admitted for a non-cardiac reason with no arrhythmia risk
Temporary pacing, or second- or third-degree AV block Long-term stable pacemaker patients admitted for unrelated reasons
- Initiation of a proarrhythmic drug such as dofetilide or sotalol
- Moderate to severe electrolyte derangement, particularly potassium and magnesium
Telemetry is a limited resource and a source of alarm burden, immobility and cost. Ask on every shift whether the original indication still exists. Nurse-driven discontinuation protocols reduce monitored days without harming outcomes and are one of the few interventions that reduce alarm volume at the source.
Alarm Fatigue
Alarm safety is a Joint Commission National Patient Safety Goal. Observational work in adult and paediatric units has repeatedly found that the large majority of physiologic monitor alarms — commonly reported above 85%, and in some ICU series above 95% — are false or non-actionable. The evidence-based bundle is unglamorous and entirely nursing-owned:
Change electrodes daily and prepare the skin: clip rather than shave hair, lightly abrade the stratum corneum, and dry thoroughly. Dried-out gel is the single largest source of artifact alarms.
Customise alarm parameters to the individual patient on admission and after any change in condition, rather than leaving factory defaults. A patient in permanent atrial fibrillation does not need an irregular-rhythm alarm.
Widen heart-rate limits to clinically meaningful values, apply short delays to SpO2 and arrhythmia alarms so that transient artifact self-resolves, and disable duplicate or redundant alarm categories.
Escalate persistent artifact rather than silencing it repeatedly.
Lead Selection and Placement
For a five-electrode system, place RA below the right clavicle, LA below the left clavicle, LL on the left lower abdomen or anterior axillary line below the costal margin, RL as the mirror image on the right, and the chest electrode in the true V1 position at the fourth intercostal space, right sternal border. Place electrodes on flat soft tissue, not over bone or heavy muscle , and avoid defibrillation pad and sternotomy sites.
Lead II is the best lead for P waves and atrial activity , and is the appropriate default for rhythm surveillance.
V1, or MCL1 when only three electrodes are available, is the lead that distinguishes ventricular tachycardia from supraventricular tachycardia with aberrancy and identifies bundle branch morphology. Monitor V1 together with lead II whenever the system allows.
For ischemia monitoring, select the ischemia fingerprint lead — the lead that showed the greatest ST deviation on the presenting 12-lead ECG — and keep the electrode positions marked and unchanged so that serial comparisons are valid.
A derived or reduced-lead 12-lead display is a screening tool. It does not replace a standard diagnostic 12-lead ECG when ischemia is suspected.
Artifact Recognition
Sixty-hertz interference from nearby electrical equipment, wandering baseline from respiration or a loose electrode, muscle tremor from shivering or Parkinson disease, tooth-brushing or scratching producing pseudo-ventricular-tachycardia, chest compressions, and dialysis or continuous renal replacement circuits all generate convincing false rhythms. The discipline is symmetrical: look at the patient before you treat the monitor, and look at the patient before you dismiss the monitor. A pulse, a perfusion assessment and a printed strip settle nearly every question.
Governance and Documentation
Every remote programme needs a named owner for each alert type, a defined response window, an after-hours pathway, and closed-loop documentation of the alert, the assessment, the action and the notification. Rhythm strips are documented per policy at shift change and with any change. Transmitted data are protected health information, so patient portals and monitoring vendors are subject to the same privacy handling as any part of the record.